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CASE PRESENTATION
VS was a healthy, athletic, 33-year-old married black
woman who presented on 30 March 1990 with ‘flu-like’
symptoms of fever, sore throat, and a slowly progressive
headache. She was given symptomatic treatment and,
because the right frontal headache worsened, she was
given Tylenol (acetaminophen) no. 3 and evaluated with
a magnetic resonance imaging (MRI) of her head, which
was said to show ‘prominent blood vessels.’ A lumbar
puncture was normal except for a ‘few red blood cells.’
Several days later she presented to an emergency room
with worsening headache and was started on Medrol
(methylprednisolone). Her headache decreased, but
within a few days she developed progressive left leg
weakness, weakness of the left arm, and decreased vision,
and on 16 April 1990 she was hospitalized. Slurred speech
was noted and a repeat MRI on 18 April 1990 suggested
a right occipital infarct. That apparently caused her to
become progressively less responsive and to develop
seizure activity, which was treated with Dilantin
(phenytoin sodium). On 20 April 1990, left hemiparesis
was noted and her responsiveness decreased; she had no
spontaneous speech, and she was transferred to the
Neurology ICU. Prior to transfer her laboratory results
(including erythrocyte sedimentation rate, platelets, white
blood cells, hematocrit (HCT), prothrombin time (PT),
partial thromboplastin time (PTT), electrolytes, and thyroid
tests) were normal.
She had had a kidney infection in 1988 and a history of
a possible dye reaction during an infertility evaluation in
1982. She was a non-smoker, did not use illicit drugs or
alcohol, had no known drug allergies, and was not taking
regular medication. Her family history was positive for
breast and colon cancer and possibly diabetes.
Physical exam upon arrival was unremarkable
except for the neurologic findings and slightly elevated
blood pressure (BP); respirations were spontaneous,
temperature 98.9 1F, heart rate 68–90, BP 150/90, neck
supple without adenopathy, clear lungs, and normal heart,
abdomen, skin, musculoskeletal and peripheral vascular
system. Neurologic exam: unconscious, no spontaneous
speech, normal funduscopic exam, asymmetric pupils
(R 4 mm, L 3 mm), left hemiplegia, withdrew right arm and
left leg to painful stimuli, and spontaneously moved right
leg. No bruits, masses, or telangiectasias were noted.
At the time of admission, laboratory data (including
blood count, blood chemistries, ESR, arterial blood gases,
serum protein electrophoresis, cryoglobulins, antinuclear
antibody (ANA), PT, PTT, and serology) were normal
except for an elevated blood sugar (190 mg dl1). The
Dilantin level was in a therapeutic range. Head computed
tomography (CT) showed diffuse cerebral infarction
involving both hemispheres with edema resulting in
right-to-left shift. Cerebral angiograms showed generalized
edema and multiple areas of stenosis vs spasm in large
vessels of the vertebral, basilar, and anterior circulation
(Figures 1–3) that were interpreted as cerebral vasculitis.
The hospital course was one of progressive neurologic
deterioration. She was started on intravenous acyclovir,
Decadron (dexamethasone), and mannitol upon
admission and given supportive care. Dilantin was
continued, and a labetalol drip was started. Signs of
transtentorial herniation developed, and fluctuations in
the BP and pulse, which varied from 50 to 150, were
noted. BP usually varied from 110 to 180 systolic and from
60 to 100 diastolic, but was 190/120 just before death on
23 April 1990. Temperature was only slightly increased to
99.6 1F until 23 April 1990 when it was noted to be 102 1F.
CLINICAL DIAGNOSIS
An abdominal ultrasound and CT scan of the abdomen
showed a 2.0 3.0 cm retroperitoneal para-aortic mass, and
a 131I-metaiodobenzylguanidine (MIBG) scintigram revealed
uptake in this area, which indicated that the mass was
almost certainly a pheochromocytoma. The adrenal glands
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appeared normal. A limited autopsy was obtained, and
a right retroperitoneal pheochromocytoma (4.0 3.0
2.8 cm) was found.1
This report indicates the extreme importance of consider-
ing pheochromocytoma as the cause of fluctuating neuro-
logic symptoms—especially when associated with episodes of
hypertension and tachycardia. The segmental narrowing of
cerebral arteries, which suggested a vasculopathy, most likely
resulted from vasoconstriction due to excess circulating nor-
epinephrine. Acute infusions of norepinephrine or epi-
nephrine or dopamine in the rat revealed that only
norepinephrine decreased cerebral blood flow, undoubtedly
the result of a1-receptor stimulation of vascular smooth
muscle.1
DISCUSSION
This case illustrates the vagaries of pheochromocytoma, one
of the most treacherous and deceptive of all diseases. The
manifestations of this relatively rare neuroendocrine tumor
are so diverse that it has been correctly designated ‘the great
mimic.’ Consequently, it is often a challenge to the diagnostic
acumen of the clinician and explains why these tumors (or
extra-adrenal pheochromocytomas, also known as paragan-
gliomas) are not recognized in over 50% of cases. To avoid
missing the diagnosis, it is crucial that clinicians think of
pheochromocytoma whenever confronted with a patient
having sustained and/or paroxysmal hypertension or any
manifestations of hypercatecholaminemia. It is estimated that
0.1–0.2% of individuals with diastolic hypertension have
pheochromocytoma.2 Of great value in recognizing these
tumors is the occurrence of hypertension simultaneously
with manifestations of hypercatecholaminemia.2
Rarely, pheochromocytomas may not cause hypertension
or manifestations; this is especially true when they are
familial, which comprises up to 30% of pheochromocytomas.
Left unrecognized and untreated, they almost invariably
cause catastrophic complications or death. Since familial
pheochromocytoma may coexist with multiple endocrine
neoplasia (type 2a, 2b), von Hippel–Lindau disease (VHL),
Figure 1 | Lateral view of subtraction cerebral angiogram
(common carotid injection) revealing marked segmental
narrowing of the anterior cerebral artery (arrow on left), middle
cerebral artery (arrow in middle), and posterior cerebral artery
(arrow on right). Figure taken from Manger, WM, Gifford, RW.
Clinical and Experimental Pheochromocytoma. Blackwell Science, 1996
(Figure 7.6, on pp 338).
Figure 2 | Anteroposterior view of subtraction cerebral
angiogram (common carotid injection) revealing marked
segmental narrowing of middle cerebral artery (arrow on right)
and marked segmental narrowing of anterior cerebral artery
(arrow on left). Figure taken from Manger, WM, Gifford, RW.
Clinical and Experimental Pheochromocytoma. Blackwell Science, 1996
(Figure 7.7 on pp 339).
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neurofibromatosis 1, carotid body tumors or other head and
neck paragangliomas, hypertension in any of these should
prompt a search for catecholamine–secreting tumors. If
familial disease is established, first-degree relatives should be
evaluated appropriately for gene mutations that cause
specific syndromes (multiple endocrine neoplasia 2a or 2b,
VHL, neurofibromatosis 1) and the succinate dehydrogenase
genes (SDHD and SDHB) often associated with head and
neck and occasionally other paragangliomas.2–5
Clinical manifestations
It is important to be aware of the varied clinical presentations
of pheochromocytoma. Sustained, labile, or paroxysmal
hypertension is caused by excess circulating catecholamines
and may be accompanied by severe hypertensive headaches,
generalized inappropriate sweating, and palpitations (with
tachycardia or occasionally reflex bradycardia). Additionally,
individuals may experience severe anxiety, tremors, pains in
the chest or abdomen, nausea, vomiting, heat intolerance,
weakness, fatigue, hypertension alternating with hypotension,
paresthesias, pallor of the face and upper body (rarely
flushing), and rarely seizures may occur. These manifesta-
tions are usually much more prominent with paroxysmal
hypertension, whereas sustained hypertension is more
frequently associated with visual impairment, orthostatic
hypotension, weight loss, and constipation; with intense
prolonged vasoconstriction of the mesenteric artery, intes-
tinal necrosis and obstruction may occur.
Hypertensive episodes during micturition or bladder
distension may occur with bladder pheochromocytomas.
Vasoactive intestinal peptide, serotonin, or calcitonin,
secreted by some pheochromocytomas, may cause diarrhea,
sometimes accompanied by hypokalemia, hypochlorhydria,
or achlorhydria. Clinical manifestations may result from
coexisting endocrine tumors and VHL.
Episodic hypertension with some of the above manifes-
tations usually occurs weekly but may occur several times
daily or only every few months; 80% last less than 1 h. Attacks
may be precipitated by palpating the tumor, postural
changes, exertion, anxiety, trauma, pain, ingestion of foods
or beverages containing tyramine (certain cheeses, beers, and
wines), and the use of certain drugs: histamine, betahistine,
phenothiazines, glucagon, tyramine, dopamine D2 receptor
antagonists (for example, metoclopramide and sulpiride),
adrenocorticotropic hormone, metyropone, b-adrenergic
blockers, angiotensin II and its analogues, tricyclic anti-
depressants, opiate analgesics, naloxone, monoamine oxidase
inhibitors, sympathomimetics, steroids (for example, predni-
sone, dexamethasone), and cafergot. The serious risk
of administering adrenocorticotropic hormone is well
established.6
Older radiocontrast agents posed a slight risk of inducing
a hypertensive crisis; however, low-osmolality ionic radio-
graphic agents and non-ionic contrast media rarely cause
any untoward reactions unless there is significant renal
impairment or an allergic reaction. Hypertensive crises with
intubation or anesthesia induction should suggest pheochro-
mocytoma.
Differential diagnosis
The differential diagnosis has been discussed in detail
elsewhere.1,7 It is important to recognize the variety of condi-
tions listed in Table 1 that may mimic pheochromocytoma.
Many of these conditions can be excluded clinically, but
it is important to recognize that some of these conditions
and many types of physiological stress can elevate plasma
and urinary catecholamines and their metabolites; however,
relatively few conditions elevate concentrations to levels
usually occurring in patients with pheochromocytoma.
Recent reports of patients with obstructive sleep apnea
presenting as a pheochromocytoma indicate the importance
of considering this condition in the differential diagnosis;
elevated urine and plasma norepinephrine were normalized
by continuous positive airways pressure.8
Resistance to antihypertensive medication or hypertensive
reactions to any of the drugs or conditions listed above
Figure 3 | Lateral view of subtraction cerebral angiogram
(vertebral artery injection) revealing segmental narrowing of
basilar artery (arrow). Figure taken from Manger, WM, Gifford, RW.
Clinical and Experimental Pheochromocytoma. Blackwell Science, 1996
(Figure 7.8 on pp 339).
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should suggest that a patient may be harboring a pheochromo-
cytoma. It is especially important to recall that severe
headaches, if accompanied by hypertension, may be caused
by pheochromocytoma; too often the headache is ascribed to
migraine. Also, it is crucial to always consider pheochromo-
cytoma as a cause of hypertension developing in pregnancy,
before concluding that the hypertension is due to pre-
eclampsia. Rare presentations, especially important to
recognize, are unexplained shock that may be accompanied
by abdominal pain, pulmonary edema, and pronounced
mydriasis unreactive to light.9 Rarely, hemorrhagic necrosis
in a pheochromocytoma presents as an acute abdomen.
Another rare presentation is multisystem organ failure
accompanied by severe hypertension or hypotension, ence-
phalopathy, hyperpyrexia, and lactic acidosis, that is,
pheochromocytoma multisystem crisis.10 Finally, it is ex-
tremely important to appreciate that congestive heart failure
may be caused by catecholamine cardiomyopathy, since
appropriate treatment may markedly improve or restore
cardiac function to normal.
Diagnosis
Table 2 lists findings that can be helpful clues that suggest the
presence of a pheochromocytoma.
When pheochromocytoma is suspected, the diagnosis is
usually not difficult. Perhaps 95% of individuals with a
sporadic (non-familial) pheochromocytoma have sustained
and/or paroxysmal hypertension with varied clinical mani-
festations mentioned above. Plasma and 24-h urine meta-
nephrine and normetanephrine are more sensitive than
other biochemical tests for detecting sporadic and familial
pheochromocytoma (Table 3).11,12 Normal values for these
metabolites in the plasma or urine almost eliminate the
presence of a pheochromocytoma. It must be appreciated
that in addition to some of the conditions mentioned in
Table 1, certain stressful conditions (for example, strenuous
exercise, myocardial infarction, congestive heart failure,
hypoglycemia, hypotension, increased intracranial pressure,
hypoxia, acidosis, surgery, severe trauma) and certain illicit
non-prescription and prescription drugs may activate the
adrenergic system and increase catecholamine secretion. Also,
a variety of drugs (for example, isoproterenol, methyldopa,
levodopa, catecholamines, sympathomimetics, tricyclic anti-
depressants, acetaminophen, phenoxybenzamine, a- and
b-adrenergic blockers, labetalol, calcium channel blockers,
and buspirone) may cause actual or spurious elevations of
urinary and plasma catecholamines and their metabolites.
Since phenoxybenzamine is frequently used to control BP
in patients with pheochromocytoma, biochemical testing
should be performed, if possible, before using this drug.
Sudden cessation of clonidine may elevate plasma and urine
catecholamines and their metabolites, whereas metyrosine
may reduce catecholamines and their metabolites.
Assays of plasma metanephrine and normetanephrine
or catecholamines drawn from an indwelling catheter in
patients recumbent for 30 min usually differentiate neuro-
Table 2 | Always consider pheochromocytoma in patients
with
Hypertension of unknown cause
Any manifestations of hypercatecholaminemia
Resistance to antihypertensive drugs
Paroxysmal BP m during b-blocker Rx
BP m caused by conditions that precipitate attacks
Severe headaches with BP m (may erroneously suggest migraine)
Hyperglycemia without known diabetes
Unexplained cardiomyopathy
Neurofibromatosis and hypertension
Syndromic (familial) pheochromocytoma
Postural hypotension (in the absence of antihypertensive Rx)
From Manger.2
Table 3 | Sensitivity and specificity of biochemical tests for
diagnosing pheochromocytoma
Sensitivity Specificity
Hereditary
(%)
Sporadic
(%)
Hereditary
(%)
Sporadic
(%)
Plasma
Free metanephrinesa 98 99 96 82
Catecholamines 68 92 89 72
Urine
Fractionated
metanephrinesa
97 99 82 45
Catecholamines 76 90 96 75
Total metanephrines 60 88 97 89
Vanillylmandelic acid 43 76 99 86
aBoth metanephrine and normetanephrine determined.
From Manger and Eisenhofer.11
Table 1 | Conditions that may suggest pheochromocytoma
1 Anxiety, panic attacks with labile blood pressure
2 Migraine
3 Paroxysmal atrial tachycardia
4 Hyperdynamic b-adrenergic circulatory state
5 Pre-eclampsia (eclampsia with convulsions)
6 Unexplained shock
7 Unexplained multisystem organ failure and lactic acidosis
8 Cardiomyopathy (with failure)
9 Baroreflex failure
10 Familial dysautonomia (Riley–Day syndrome)
11 Carcinoid
12 Neuroblastoma
13 Drug-induced hypertension
14 Factitiously produced hypertension
15 Cushing’s syndrome
16 POTS
17 Acute infectious disease
18 Autonomic hyper-reflexia
19 Hyperthyroidism
20 Menopause
21 Hyperglycemia without diabetes mellitus
22 Acrodynia (‘pink disease’—mercury poisoning)
23 Cerebral vasculitis
24 Sleep apnea
POTS, postural tachycardia syndrome.
Plasma and urine catecholamines and their metabolites may be elevated in
conditions italicized.
From Manger and Gifford1 and Manger7 with modification.
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genic from pheochromocytic hypertension. Rarely, a cloni-
dine suppression test may be indicated to differentiate these
types of hypertension; suppression of plasma normeta-
nephrines to more than 40% or to normal levels excludes
pheochromocytoma in about 96% of cases.13 A glucagon
stimulation test is never needed today.
Imaging studies to localize adrenal and extra-adrenal
pheochromocytomas are essential for the surgeon, but they
are only justified when the diagnosis has been established
biochemically; however, some familial tumors may rarely be
identified by imaging before biochemical tests become
positive. CT can identify 95% of adrenal pheochromo-
cytomas (1 cm or larger), and it can localize 90% of extra-
adrenal abdominal and pelvic tumors larger than 2 cm. It can
also detect chest tumors, although intrapericardial pheo-
chromocytomas may be missed. CT requires intravenous and
oral contrast for optimal visualization. MRI is more reliable
than CT in detecting pheochromocytomas, and signal
intensity on T2-weighted images can be fairly characteristic
for pheochromocytomas; and only rarely will other benign or
malignant tumors resemble pheochromocytomas. CT arti-
facts caused by surgical clips do not interfere with MRI, and
the contrast agents, which are necessary for optimal
visualization with CT, are not required for MRI. Further-
more, contrast media used with CT may cause allergic
reactions, which are almost never caused by gadolinium
contrast media (given intravenously), often used with MRI.
However, contrast agents should be avoided in patients with
severe renal impairment. MRI is superior to CT in detecting
extra-adrenal, abdominal, pelvic, some cardiac, and familial
pheochromocytomas.1,2 Liver metastases are best detected by
CT or MRI. Because no radiation is involved with MRI, it is
ideal for imaging pregnant patients and children suspected of
harboring a pheochromocytoma.
Uptake of 131I-MIBG occurs in up to 85% of pheochromo-
cytomas and is highly specific (95–100%). 123I-MIBG also
possesses this specificity and it can detect about 90% of
tumors. MIBG scintigraphy may be very helpful in detecting
adrenal medullary hyperplasia, small and extra-adrenal
pheochromocytomas, and metastases, because it scans the
entire body. MIBG uptake may occur in neuroblastomas,
medullary thyroid carcinoma, carcinoids, and small-cell-lung
cancers. As MIBG uptake may be inhibited by labetalol,
reserpine, calcium channel blockers, tricyclic antidepressants,
sympathomimetics, cocaine, adrenergic neuron blockers,
and some tranquilizers, these drugs should be discontinued
at least 1 week before scintigraphy.1,2 Bone scanning with
(TC)99m may occasionally demonstrate metastatic lesions
missed by MIBG. 111Indium octreotide is another radio-
pharmaceutical agent taken up by some pheochromocytomas
with somatostatin receptors, but it only detects 25% of
tumors; occasionally it may detect metastases missed by
131I-MIBG.
If MRI and CT do not demonstrate pheochromocytomas
in the abdomen and pelvis, MRI of the chest and neck is
recommended. When available, whole-body MIBG scan
should be performed to help establish that a tumor
is a pheochromocytoma and to detect any metastases
before operation. More recently, 6-[18F]fluorodopamine
positron emission tomography scan was reported superior
to 131I-MIBG scintigraphy in locating metastatic pheochro-
mocytoma,14 but it is not generally available. If efforts fail to
localize a pheochromocytoma, determination of catechola-
mines in blood sampled from various sites in the vena cava
may permit localization.1
Incidentalomas (incidentally recognized adrenal masses)
are encountered in 3–4% of patients undergoing abdominal
CT scan. Furthermore, one large survey indicated that 4.2%
of incidentalomas are pheochromocytomas.15 Although MRI
and MIBG may strongly suggest pheochromocytoma,
demonstration of significantly elevated plasma and urinary
catecholamines or their metabolites is essential to establish
the diagnosis.
Treatment
Preoperative, operative, and postoperative management of
benign and malignant pheochromocytoma are discussed in
detail elsewhere.1,11 With improved imaging techniques,
laparoscopic removal of adrenal and some extra-adrenal
pheochromocytomas is usually performed. Open transper-
itoneal surgical exploration of the abdomen is indicated
when tumors are multiple, very large, or difficult to remove
laparoscopically. Generally, pheochromocytomas should be
removed expeditiously. Familial pheochromocytoma always
must be considered, and patients should be evaluated for
medullary thyroid carcinoma, C-cell hyperplasia, hyper-
parathyroidism, VHL, and for succinate dehydrogenase
mutations, especially if carotid body tumors and pheo-
chromocytomas coexist. As mentioned above, evidence of
familial disease requires that first-degree relatives be eval-
uated genetically for pheochromocytoma and coexisting
disease.
Pheochromocytoma in the bladder, chest, or neck requires
special surgical procedures. During pregnancy, tumors
should be removed promptly; however, if pregnancy is
carried to term to permit fetal maturity, cesarean section is
advisable to avoid the stress of labor and vaginal delivery.
In the presence of malignant pheochromocytomas with
metastases, it is usually desirable to resect as much tumor
tissue as possible to reduce the amount of catecholamines
entering the circulation. Radiotherapy with 131I-MIBG may
reduce tumor size and catecholamine secretion. Intravenous
chemotherapy with cyclophosphamide, vincristine, and
dacarbazine is usually reserved to treat aggressive metastatic
tumors, particularly if they are symptomatic and causing
pain or pressure on vital structures. Treatment with a
combination of 131I-MIBG and chemotherapy may provide
greater therapeutic benefit than either alone.16 X-ray radi-
ation may be helpful in treating bone metastases. a- and
b-blockers may control hypertension and symptomatology
for many years, and metyrosine can markedly inhibit cate-
cholamine synthesis and reduce symptoms. b-Blockers and
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metyrosine may prevent or minimize catecholamine cardio-
myopathy.1,2 Occasionally, patients with metastatic pheo-
chromocytoma develop a hypersecretory disorder (due to
vasoactive intestinal peptide secretion), with severe diarrhea
that may be benefited by somatostatin (given intravenously).
Alternatives to surgical resection, radiopharmaceutical
therapy, chemotherapy, and radiotherapy include external
beam radiation, cryoablation, radiofrequency ablation, and
transcatheter embolization of hepatic metastases.17
Finally, the dictum to recall is ‘think of it; diagnose it
biochemically, localize it with imaging studies, treat it appro-
priately, and remove it expeditiously, whenever possible.’
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